COMMUNIQUÉS West-GlobeNewswire

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
13/07/2026
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical development ZIMA-101 represents the first [...]
Sienna Senior Living Named One of Canada's Best Companies by TIME and Statista for Second Consecutive Year
13/07/2026
MARKHAM, Ontario, July 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") is proud to announce it has been named one of Canada's Best Companies by TIME and Statista for the second [...]
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
13/07/2026
INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLC Outcomes continue to compare favourably with historical benchmarks [...]
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, [...]
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
13/07/2026
Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration TUCSON, Ariz., July 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard [...]
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/07/2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to [...]
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
13/07/2026
Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE [...]
Novo Nordisk A/S - share repurchase programme
13/07/2026
Bagsværd, Denmark, 13 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Solésence Brings Patent-Backed Skin Health Innovation to Hair and Scalp
13/07/2026
New White Label Collection, Powered by WHSPR™ and Kleair™, Debuts with Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen Scalp Screen Dry Shampoo SPF 45+ Sunscreen Named a Finalist for the 2026 [...]
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
13/07/2026
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: [...]
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a [...]
Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference
13/07/2026
SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in Canaccord Genuity’s 46th [...]
BrewDog Waterloo to Host England's Biggest Pub Watch Party for Blockbuster Semifinal
13/07/2026
England’s biggest pub comes alive for a blockbuster semifinal, delivering the atmosphere, the passion and an unforgettable football watch party as fans rally behind England LONDON, July 13, 2026 (GLOBE NEWSWIRE) -- [...]
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026
New executive leadership role to accelerate innovation, modernize technology, and advance the company's long-term growth strategy MCLEAN, Va., July 13, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health [...]
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
13/07/2026
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim [...]
Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil
13/07/2026
COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) [...]
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. [...]
First patient treated in Phase 2 A-TANGO trial for acute-on-chronic liver failure
13/07/2026
Randomized phase 2 study evaluating Yaqrit’s toll-like receptor 4 (TLR4) antagonist YAQ005 alone and in combination with G-CSF for acute-on-chronic liver failure (ACLF) Investigational combination G-TAK is designed to [...]

Pages